Skip to main content

Lotronex Disease Interactions

There are 4 disease interactions with Lotronex (alosetron).

Major

Alosetron (applies to Lotronex) gastrointestinal complications

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation, Constipation

Alosetron is contraindicated in patients with a history of severe bowel complications. Patients with serious complications of constipation, including history of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; obstruction, ileus, impaction, toxic megacolon, secondary bowel ischemia, and impaired intestinal circulation should not use alosetron. Care should be exercised when using this agent in patients at risk.

References

  1. "Product Information. Lotronex (alosetron)." Glaxo Wellcome PROD (2001):
Major

Alosetron (applies to Lotronex) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Alosetron is extensively metabolized by the liver. The use of alosetron is contraindicated in patients with severe hepatic impairment and it should be used with caution in patients with mild or moderate hepatic impairment. Close monitoring is recommended.

References

  1. "Product Information. Lotronex (alosetron)." Glaxo Wellcome PROD (2001):
Major

Alosetron (applies to Lotronex) thrombotic disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder

The use of alosetron is contraindicated in patients with coagulation abnormalities such as thrombophlebitis, or hypercoagulable state.

References

  1. "Product Information. Lotronex (alosetron)." Glaxo Wellcome PROD (2001):
Moderate

Alosetron (applies to Lotronex) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Renal impairment has no effect on the renal elimination of alosetron due to the minor contribution of this pathway to elimination. Care should be exercised as the effect of renal impairment on metabolite pharmacokinetics and the effect of end-stage renal disease have not been assessed.

References

  1. "Product Information. Lotronex (alosetron)." Glaxo Wellcome PROD (2001):

Lotronex drug interactions

There are 71 drug interactions with Lotronex (alosetron).

Lotronex alcohol/food interactions

There is 1 alcohol/food interaction with Lotronex (alosetron).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer